45 related articles for article (PubMed ID: 20874822)
21. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
22. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma.
Chang CC; Cho SF; Chen YW; Tu HP; Lin CY; Chang CS
Clin Nucl Med; 2012 Aug; 37(8):e189-95. PubMed ID: 22785526
[TBL] [Abstract][Full Text] [Related]
23. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
24. Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.
Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Wong RH; Gaskill M; Margolis JH; Hill J; Sukari A; Chundru S; Fink-Bennett D; Nagle C
Mol Imaging Biol; 2007; 9(1):43-9. PubMed ID: 17176979
[TBL] [Abstract][Full Text] [Related]
25. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
26. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
27. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Jerusalem GH; Beguin YP
Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957
[TBL] [Abstract][Full Text] [Related]
29. Grade I lymphomatoid granulomatosis with increased uptake of [18F] fluorodeoxyglucose in positron emission tomography: a case report.
Arai H; Oshiro H; Yamanaka S; Yukawa N; Wada N; Rino Y; Watanuki Y; Yamanaka S; Inayama Y; Lee J; Nakayama H; Masuda M
J Clin Exp Hematop; 2009 May; 49(1):39-44. PubMed ID: 19474516
[TBL] [Abstract][Full Text] [Related]
30. Novel imaging techniques in NHL: clinical results with PET imaging.
Buchmann I; Reske SN
Ann Hematol; 2001; 80 Suppl 3():B54-7. PubMed ID: 11757709
[No Abstract] [Full Text] [Related]
31. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.
Dunleavy K; Mikhaeel G; Sehn LH; Hicks RJ; Wilson WH
Leuk Lymphoma; 2010 Aug; 51 Suppl 1():28-33. PubMed ID: 20658958
[TBL] [Abstract][Full Text] [Related]
32. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Kwee TC
Eur J Haematol; 2017 Apr; 98(4):337-347. PubMed ID: 27943422
[TBL] [Abstract][Full Text] [Related]
33. Current and future best practice in imaging, staging, and response assessment for Non-Hodgkin's lymphomas: the Specialist Integrated Haematological Malignancy Imaging Reporting (SIHMIR) paradigm shift.
Zafar S; Sharma RK; Cunningham J; Mahalingam P; Attygalle AD; Khan N; Cunningham D; El-Sharkawi D; Iyengar S; Sharma B
Clin Radiol; 2021 May; 76(5):391.e1-391.e18. PubMed ID: 33579517
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of
Liu Q; Yang T; Chen X; Liu Y
Front Oncol; 2023; 13():1117064. PubMed ID: 36776334
[TBL] [Abstract][Full Text] [Related]
35. Pre- and post-treatment evaluation of non-Hodgkin's lymphoma.
Mavromatis BH; Cheson BD
Best Pract Res Clin Haematol; 2002 Sep; 15(3):429-47. PubMed ID: 12468398
[TBL] [Abstract][Full Text] [Related]
36. Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.
Tomasi G; Turkheimer F; Aboagye E
Mol Imaging Biol; 2012 Apr; 14(2):131-46. PubMed ID: 21842339
[TBL] [Abstract][Full Text] [Related]
37. Interest of FDG-PET in the Management of Mantle Cell Lymphoma.
Bailly C; Carlier T; Touzeau C; Arlicot N; Kraeber-Bodéré F; Le Gouill S; Bodet-Milin C
Front Med (Lausanne); 2019; 6():70. PubMed ID: 31024918
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
